12/22
07:18 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/17
08:44 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/17
07:06 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/12
11:33 am
rytm
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says [Yahoo! Finance]
12/12
10:01 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $141.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $141.00 price target on by analysts at Canaccord Genuity Group Inc..
12/12
08:44 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
12/12
08:18 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Citizens Jmp from $141.00 to $167.00. They now have a "market outperform" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Citizens Jmp from $141.00 to $167.00. They now have a "market outperform" rating on the stock.
12/12
06:03 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/12
04:39 am
rytm
Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After Positive Prader-Willi Data and Phase 3 Trial Plans [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After Positive Prader-Willi Data and Phase 3 Trial Plans [Yahoo! Finance]
12/12
02:34 am
rytm
Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? [Yahoo! Finance]
Medium
Report
Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? [Yahoo! Finance]
12/11
05:04 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/11
04:30 pm
rytm
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster [Seeking Alpha]
Medium
Report
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster [Seeking Alpha]
12/11
04:02 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/11
03:54 pm
rytm
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript [Seeking Alpha]
Low
Report
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript [Seeking Alpha]
12/11
02:13 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $120.00 to $145.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $120.00 to $145.00. They now have a "buy" rating on the stock.
12/11
08:06 am
rytm
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome [Yahoo! Finance]
High
Report
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome [Yahoo! Finance]
12/11
07:30 am
rytm
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
High
Report
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
12/10
04:11 pm
rytm
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome [Yahoo! Finance]
12/10
04:01 pm
rytm
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
High
Report
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
11/27
06:19 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
11/25
05:35 pm
rytm
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]
Low
Report
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]
11/25
07:19 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
11/10
04:00 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $114.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $114.00. They now have a "buy" rating on the stock.
11/10
08:18 am
rytm
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 [Yahoo! Finance]
11/10
07:00 am
rytm
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
Low
Report
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025